Vaximm Seeks Funding to Pursue Cancer Vaccine Goals
Executive Summary
Privately held Vaximm is seeking investment for its clinical pipeline that includes cancer vaccine VMX01, which is in Phase II as a monotherapy and due to start clinical trials next year in combination with Merck KGaA and Pfizer's PD-L1 inhibitor, Bavencio.